Video

Matt Salo Explains How High-Cost Specialty Drugs Change the Game for Medicaid

The high cost of Gilead Science's hepatitis C drug Sovaldi is causing Medicaid to come up with new ways of handling drug costs, according to Matt Salo, executive director of the National Association of Medicaid Directors.

The high cost of Gilead Science’s hepatitis C drug Sovaldi is causing Medicaid to come up with new ways of handling such an expensive drug, according to Matt Salo, executive director of the National Association of Medicaid Directors.

He discussed high-cost specialty drugs and their effect on Medicaid at the America’s Health Insurance Plans National Conferences on Medicare and Medicaid, and Dual Eligibles Summit in Washington, DC, from September 28 to October 2.

“[Sovaldi is] great from a public health perspective; but when you multiply large unit cost times a very large number of people, this drug alone has the potential of doubling Medicaid’s pharmacy spend,” Mr Salo said.

Related Videos
Screenshot of an interview with Evangelia Vlachou, MD
Aditya Bardia, MD, MPH, FASCO, medical oncologist, UCLA Health
Screenshot of an interview with Barry Goy, MD
Gladys Antelo Allen
Dr Michael Bernstein
Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine
Debra Patt, MD, PhD, MBA, MPH
Jeff Stark, MD, vice president, head of medical immunology, UCB.
Mikkael Sekeres, MD
Kim Newcomer, director of volunteers, Colorectal Cancer Alliance
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo